{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:23:05Z","timestamp":1788214985223,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ferring Pharmaceuticals"}],"content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.crohns.2013.08.007","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T01:45:46Z","timestamp":1378259146000},"page":"200-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life"],"prefix":"10.1093","volume":"8","author":[{"given":"Christopher S.J.","family":"Probert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel U.","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oudkerk Pool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Marteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2013.08.007_bb0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2013.08.007_bb0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.SGA.0000334035.94370.f6","article-title":"Novel 5-aminosalicylic acid formulations in ulcerative colitis: old dog, new tricks","volume":"31","author":"Wilson","year":"2008","journal-title":"Gastroenterol Nurs"},{"key":"10.1016\/j.crohns.2013.08.007_bb0015","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","author":"Dignass","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200108000-00009","article-title":"Mesalazine 4g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis","volume":"7","author":"Farup","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.08.007_bb0025","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Mesalazine Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1155\/2007\/862917","article-title":"Delayed-release oral mesalamine 4.8g\/day (800mg tablets) compared to 2.4g\/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial","volume":"21","author":"Hanauer","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0035","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02065413","article-title":"Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Mesalazine UC Maintenance Study Group","volume":"40","author":"Miner","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.crohns.2013.08.007_bb0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2036.2007.03361.x","article-title":"MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials","volume":"26","author":"Sandborn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.08.007_bb0045","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1365-2036.1997.00259.x","article-title":"Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis","volume":"11","author":"Gionchetti","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.08.007_bb0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.1995.tb00421.x","article-title":"Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis","volume":"9","author":"L\u00e9mann","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.08.007_bb0055","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","article-title":"Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis","volume":"95","author":"Marshall","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0060","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.crohns.2013.08.007_bb0070","first-page":"1338","article-title":"A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults","volume":"91","author":"Kam","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0075","first-page":"1867","article-title":"A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0080","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.mib.0000231496.92013.85","article-title":"Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement","volume":"12","author":"Regueiro","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.08.007_bb0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.crohns.2009.08.003","article-title":"Mesalazine vanishing time from rectal mucosa following its topical administration","volume":"4","author":"Pimpo","year":"2010","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2013.08.007_bb0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.MIB.0000158386.25660.1e","article-title":"A new oral delivery system for 5-ASA: preliminary clinical findings for MMX","volume":"11","author":"Prantera","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.08.007_bb0095","first-page":"12","article-title":"Combined therapy with 5-aminosalicylic tablets and enemas for maintaining remission in ulcerative colitis","volume":"23","author":"d'Albasio","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00365520310008133","article-title":"Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis","volume":"39","author":"Piodi","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2036.2001.00913.x","article-title":"Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study","volume":"15","author":"Vecchi","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.08.007_bb0110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2013.08.007_bb0115","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/apt.12266","article-title":"MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis","volume":"37","author":"Flouri\u00e9","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.08.007_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0125","first-page":"41","article-title":"Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(\u00ae) mesalamine","volume":"4","author":"Nanda","year":"2012","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.crohns.2011.06.009","article-title":"Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease","volume":"5","author":"Peyrin-Biroulet","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00005650-199711000-00003","article-title":"Evaluation of index and profile measures of health status in a randomized controlled trial \u2014 comparison of the medical outcomes study 36-item short form health survey, EuroQoL and Disease Specific Measures","volume":"35","author":"Jenkinson","year":"1997","journal-title":"Med Care"},{"issue":"Suppl. 1","key":"10.1016\/j.crohns.2013.08.007_bb0140","first-page":"S-521","article-title":"Early response to combined oral and topical mesalazine (Pentasa\u00ae) for ulcerative colitis: post-hoc analysis of efficacy at two weeks in the PINCE trial","volume":"138","author":"Marteau","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.08.007_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000235916","article-title":"Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis","volume":"80","author":"Connolly","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.crohns.2013.08.007_bb0150","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2011.04800.x","article-title":"Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis \u2014 additional results from two controlled studies","volume":"34","author":"Sandborn","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.08.007_bb0155","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.3748\/wjg.15.4353","article-title":"5-ASA in ulcerative colitis: improving treatment compliance","volume":"15","author":"Prantera","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.08.007_bb0160","first-page":"893","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"Karagozian","year":"2007","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.crohns.2013.08.007_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1756283X12461395","article-title":"Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma","volume":"6","author":"Probert","year":"2013","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S187399461300278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S187399461300278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/8\/3\/200\/1411187\/8-3-200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T03:27:06Z","timestamp":1503458826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2013.08.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S187399461300278X"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2013.08.007","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2013.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}